Haemonetics Co. (NYSE:HAE) Position Increased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its position in shares of Haemonetics Co. (NYSE:HAE) by 0.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 801,049 shares of the medical instruments supplier’s stock after buying an additional 5,668 shares during the quarter. Allspring Global Investments Holdings LLC owned 1.60% of Haemonetics worth $62,802,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of HAE. Nisa Investment Advisors LLC lifted its stake in Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 632 shares in the last quarter. KBC Group NV lifted its stake in Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after buying an additional 712 shares in the last quarter. iSAM Funds UK Ltd purchased a new stake in Haemonetics during the third quarter valued at about $204,000. CWC Advisors LLC. purchased a new stake in Haemonetics during the third quarter valued at about $231,000. Finally, Versor Investments LP lifted its stake in Haemonetics by 9.1% during the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock valued at $289,000 after buying an additional 300 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Trading Up 1.6 %

NYSE:HAE opened at $62.27 on Friday. The stock’s 50 day moving average price is $74.92 and its 200 day moving average price is $77.69. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company has a market capitalization of $3.13 billion, a P/E ratio of 24.51, a P/E/G ratio of 0.98 and a beta of 0.39. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.09 and a current ratio of 3.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, research analysts forecast that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock. JMP Securities dropped their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, February 7th. Barrington Research dropped their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $95.00 to $68.00 in a report on Friday, February 7th. Finally, Raymond James reiterated a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.